Atea and Roche get a Covid-19 antiviral warning
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
Valneva scores a pyrrhic trial win
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Atea and Roche get a Covid-19 antiviral warning
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
Valneva scores a pyrrhic trial win
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
